<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00639587</url>
  </required_header>
  <id_info>
    <org_study_id>A00275</org_study_id>
    <nct_id>NCT00639587</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Cetirizine Tablets Versus Ketotifen Dry Syrup in Children With Perennial Allergic Rhinitis</brief_title>
  <official_title>A Double-blind, Parallel, Active Comparator Controlled, Randomized Trial; Comparison of the Efficacy and Safety in Children With Perennial Allergic Rhinitis of Cetirizine Tablets Versus Ketotifen Dry Syrup</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ketotifen is an established antihistamine drug, widely used in pediatric clinical practice in
      Japan. The objective of the study was to compare the efficacy and safety of cetirizine
      hydrochloride versus ketotifen dry syrup on children 7 years and older with perennial
      allergic rhinitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">March 2003</completion_date>
  <primary_completion_date type="Actual">March 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total symptom score (TSS) (nasal symptom score [sneezing, nasal discharge, nasal congestion] and rhinoscopy results) Safety: adverse events and laboratory assessments</measure>
    <time_frame>TSS: 2 weeks - Safety: 3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total 2 symptoms score (T2SS) (sneezing, nasal discharge) Global Improvement Rating</measure>
    <time_frame>T2SS: 2 weeks - Global Improvement Rating: at the end of the 2-week-treatment period</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">149</enrollment>
  <condition>Rhinitis, Allergic, Perennial</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketotifen</intervention_name>
    <description>Ketotifen dry syrup 0.1%; 1 mg b.i.d.; for 2 weeks</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetirizine</intervention_name>
    <description>Cetirizine tablet; 10 mg o.d.; for 2 weeks and 5 mg b.i.d.; for 2 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  had at least one of the 3 symptoms: sneezing, nasal discharge or nasal congestion;

          -  severity of nasal symptoms was moderate to severe during the observation period;

          -  criteria for allergic etiology of the disease fulfilled, i.e., positive IgE antibody
             test and positive eosinophil count in nasal discharge.

        Exclusion Criteria:

          -  history of hypersensitivity to the ingredients of cetirizine or ketotifen formulation
             or to hydroxyzine;

          -  history of drug hypersensitivity;

          -  history of convulsive disorder;

          -  vasomotor rhinitis or eosinophilic rhinitis;

          -  asthma requiring treatment with adrenocortical hormones;

          -  concomitant diseases which could impede the efficacy evaluation of the study drug;

          -  subjects in the ascending-dose phase of hyposensitization therapy or non-modular
             therapy and who had not received the maintenance dosage;

          -  pollen allergy;

          -  malignant neoplasm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1-877-822-9493 (UCB)</affiliation>
  </overall_official>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2008</study_first_submitted>
  <study_first_submitted_qc>March 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2008</study_first_posted>
  <last_update_submitted>September 3, 2009</last_update_submitted>
  <last_update_submitted_qc>September 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>UCB</organization>
  </responsible_party>
  <keyword>Cetirizine</keyword>
  <keyword>Zyrtec</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetirizine</mesh_term>
    <mesh_term>Ketotifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

